Incyte Corporation (INCY)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 316,630 | 834,215 | 529,116 | 570,444 | -232,218 |
| Revenue | US$ in thousands | 4,241,220 | 3,693,100 | 3,394,640 | 2,986,270 | 2,666,700 |
| Pretax margin | 7.47% | 22.59% | 15.59% | 19.10% | -8.71% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $316,630K ÷ $4,241,220K
= 7.47%
Incyte Corporation's pretax margin has exhibited fluctuations over the past five years as follows:
- As of December 31, 2020, the pretax margin was at a negative 8.71%, indicating that the company's expenses exceeded its revenues before accounting for taxes.
- By December 31, 2021, the pretax margin had significantly improved to 19.10%, reflecting a more efficient management of costs relative to revenues.
- In the subsequent year ending December 31, 2022, the pretax margin slightly decreased to 15.59%, possibly due to shifts in the company's cost structure or revenue generation.
- As of December 31, 2023, the pretax margin surged to 22.59%, signaling a strong performance in terms of profitability before taxes.
- However, by December 31, 2024, the pretax margin declined to 7.47%, potentially indicating challenges in maintaining profitability levels.
Overall, Incyte Corporation's pretax margin has shown variability, suggesting the need for continued monitoring and potential adjustments to optimize its profitability levels.
Peer comparison
Dec 31, 2024